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Background: This prospective multicenter study assessed the prognostic inﬂuence of the extent of resection when
compared with biopsy only in a contemporary patient population with newly diagnosed glioblastoma.
Patients and methods: Histology, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status,
and clinical data were centrally analyzed. Survival analyses were carried out with the Kaplan–Meier method. Prognostic
factors were assessed with proportional hazard models.
Results: Of 345 patients, 273 underwent open tumor resection and 72 biopsies; 125 patients had gross total resections
(GTRs) and 148, incomplete resections. Surgery-related morbidity was lower after biopsy (1.4% versus 12.1%,
P = 0.007). 64.3% of patients received radiotherapy and chemotherapy (RT plus CT), 20.0% RT alone, 4.3% CT alone,
and 11.3% best supportive care as an initial treatment. Patients ≤60 years with a Karnofsky performance score (KPS) of
≥90 were more likely to receive RT plus CT (P < 0.01). Median overall survival (OS) (progression free survival; PFS) ranged
from 33.2 months (15 months) for patients withMGMT-methylated tumors after GTR and RT plus CT to 3.0 months (2.4
months) for biopsied patients receiving supportive care only. Favorable prognostic factors in multivariate analyses for OS
were age ≤60 years [hazard ratio (HR) = 0.52; P < 0.001], preoperative KPS of ≥80 (HR = 0.55; P < 0.001), GTR
(HR = 0.60; P = 0.003),MGMT promoter methylation (HR = 0.44; P < 0.001), and RT plus CT (HR = 0.18, P < 0.001);
patients undergoing incomplete resection did not better than those receiving biopsy only (HR = 0.85; P = 0.31).
Conclusions: The value of incomplete resection remains questionable. If GTR cannot be safely achieved, biopsy only
might be used as an alternative surgical strategy.
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introduction
Glioblastoma is the most frequent and most aggressive primary
brain tumor in adults [1]. The combined radio- and
chemotherapy (RT plus CT) has become the standard of care [2]
and has substantially improved the prognosis, particularly for
tumors exhibiting a methylated promoter of the gene encoding
O6-methylguanine-DNAmethyltransferase (MGMT) [3]. Gross
total resection (GTR) before adjuvant treatment has also been
shown to gain a favorable impact on outcome [4–6]. In contrast,
the prognostic place of incomplete resection when compared with
biopsy only is not yet clearly deﬁned [2]. The elucidation of this
question is important since GTR cannot be always achieved [7, 8].
This multicenter observational study was conducted to identify
prognostic factors in glioblastoma patients treated according to
current standards of care. Based on our previous analysis on
nonresectable glioblastomas demonstrating surprisingly long
survival after biopsy only in the era of RT plus CT [9], we awaited
similar survival rates after incomplete resection and biopsy only.
patients andmethods
study design
The German Glioma Network (GGN) has generated a prospective
longitudinal database to follow patients with newly diagnosed glioblastoma.
Patients were recruited from October 2004 until March 2009; database
closure was March 2012. All patients gave informed consent. Data collection
at enrolment and follow-up addressed important patient-, tumor-, and
treatment-related parameters, includingMGMT promoter methylation
status. The extent of open resection (EOR) was determined locally by early
(<72 h) postoperative magnetic resonance imaging (MRI) and scored
according to the study of Stummer et al. [10] either as GTR (no residual
contrast enhancement in T1-weighted sequences) or incomplete resection
(any contrast enhancement with a volume of more than one voxel in the T1-
weighted images). Prospective estimations of EOR were done in a blinded
fashion. No additional volumetric analyses were carried out. Central
histological review, according to the World Health Organization (WHO) [1],
was done at the Department of Neuropathology, University of Bonn. Central
determination of theMGMT promoter methylation status by methylation-
speciﬁc PCR [3] was carried out at the Department of Neuropathology,
Heinrich Heine University Düsseldorf. Data were centrally collected and
analyzed [Institute for Medical Informatics, Statistics and Epidemiology
(IMISE), University of Leipzig]. Treatment decisions were independently
rendered at each academic center. Tumor progression was assessed
according to the Macdonald criteria [11].
statistical analysis
Associations of clinical data were tested by the χ2 test, Fisher’s exact test, and
Mann–Whitney U-test. Survival data were analyzed with the Kaplan–Meier
method. A reference point was the date of ﬁrst surgery. The log-rank test was
used to compare outcome data. Multivariate analyses were carried out with
Cox regression models. P-values of ≤0.05 were considered as statistically
signiﬁcant. Statistical analyses were carried out using IBM SPSS (Version
20.0.0).
results
A total of 345 patients were analyzed. Clinical data of the study
population are summarized in Table 1. Sixty-two patients were
older than 70 years and 28 had a Karnofsky performance score
(KPS) of <70. GTR, incomplete resection, and biopsy were done
in 125 patients, 148, and 72, respectively. Biopsied patients were
older (median: 65 versus 60 years; P = 0.008), rated similarly on
the performance scale (median KPS: 80 each, P = 0.5), and had
similarly often an eloquent tumor location (23.6% versus 19.4%;
P = 0.4) when compared with those undergoing incomplete
Table 1. Summary of patients’ characteristics
All patients (N = 345)
Age at diagnosis (years)
Median 61
Range 19–86
Age classes, n (%)
≤50 years 85 (24.6)
51–60 years 83 (24.1)
61–70 years 115 (33.3)
>70 years 62 (18.0)
Gender, n (%)
Males 209 (60.6)
Females 136 (39.4)
KPS, n (%)
90–100 146 (43.2)
70–80 164 (48.5)
<70 28 (8.3)
No data 7 (–)
Surgery, n (%)
Gross total resection 125 (36.2)
Incomplete resection 148 (42.9)
Biopsy 72 (20.9)
Review diagnosis, n (%)
Glioblastoma 329 (95.4)
Giant cell glioblastoma 9 (2.6)
Gliosarcoma 7 (2.0)
MGMT promoter methylation status, n (%)
Methylated 163 (48.1)
Unmethylated 176 (51.9)
Unknown 6 (–)
Therapy, n (%)
First-line
Supportive care 39 (11.3)
RT alone 69 (20.0)
CT alone
a
15 (4.3)
RT plus CT
b
222 (64.3)
Second-line (N = 161)
Surgery alone 26 (16.1)
Surgery plus CT 44 (27.3)
Surgery plus RT plus CT 9 (5.6)
RT alone 2 (1.2)
RT plus CT 21 (13.0)
CT alone 59 (36.6)
aTemozolomide (TMZ) (n = 13) or nitrosourea (n = 2).
bConcomitant plus adjuvant TMZ (n = 164), concomitant TMZ only
(n = 42), adjuvant TMZ only (n = 12), nitrosourea (n = 4), one dose was
sufﬁcient to place a patient in this group, non-alkylating agents were
excluded, no patient received ﬁrst-line bevacizumab.
CT, alkylating chemotherapy; RT, radiotherapy; KPS, Karnofsky performance
score; MGMT, O6-methylguanine-DNAmethyltransferase.
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resection. The frequency of an eloquent tumor location was
lowest in the GTR group (14.4%; P = 0.04). Transient
complication occurred in 33 patients after resection and in 1
patient after biopsy (P = 0.007). Histopathological diagnosis
revealed 329 glioblastomas, 9 giant cell glioblastomas, and 7
gliosarcomas. A methylatedMGMT promoter was found in
48.1% of the study cohort. Methylated and unmethylated
tumors did not differ in terms of age (median: 60 versus 62
years; P = 0.4), KPS (median: 80 each, P = 0.3), EOR (P = 0.8), or
mode of ﬁrst-line treatment (P = 0.8).
64.3% of the study population patients underwent RT plus
CT. RT alone, CT alone, and supportive treatment were applied
in 20.0%, 4.3%, and 11.3%, respectively. Patients ≤60 years
(odds ratio 3.3, 95% CI 2.1–5.3) and those with KPS of ≥90
(odds ratio 3.0, 95% CI 1.8–4.8) were more likely to receive RT
plus CT. Biopsied patients were less frequently treated with RT
plus CT (odds ratio 0.5, 95% CI 0.3–0.8) and received more
often supportive care only (odds ratio 2.4, 95% CI 1.2–4.9).
treatment results and prognostic/predictive factors
Overall, 327 patients suffered from tumor progression and
310 deceased during the follow-up period. Median
progression-free survival (PFS) and median overall survival
(OS) were 6.4 and 12.8 months, respectively. Outcome
stratiﬁed for EOR when compared with biopsy, ﬁrst-line
treatment, and MGMT methylation status is given in Table 2:
outcome was best in case of RT plus CT (median PFS: 7.8
months/median OS: 17.1 months) and worst after supportive
treatment (median PFS: 2.7 months/median OS: 3.0 months;
supplementary Figure S1, available at Annals of Oncology
online). GTR was associated with superior OS (median: 17.1
Table 2. Outcome of patients stratiﬁed for the extent of resection,MGMT promoter methylation status, and treatment regimes
All patients Gross total resection Incomplete resection Biopsy
Median (95% CI) Event Median (95% CI) Event Median (95% CI) Event Median (95% CI) Event
PFS
Palliative care 2.7 (1.0–3.5) 36/39 0.7 (0.4–1.0) 8/8 2.2 (0.9–3.5) 17/17 2.4 (1.3–3.4) 11/14
RT alone 6.6 (5.9–7.3) 67/69 6.7 (5.8–7.5) 23/24 6.8 (5.3–8.2) 33/33 4.5 (2.3–6.6) 11/12
CT alone 2.4 (1.3–3.5) 14/15 – 1/1 – 4/4 2.9 (0.02–5.8) 9/10
RT plus CT 7.8 (6.6–9.0) 210/222 7.8 (4.8–10.8) 88/92 7.4 (6.2–8.5) 91/94 8.8 (4.3–13.4) 31/36
Total 6.4 (5.7–7.1) 327/345 6.7 (5.7–7.7) 120/125 6.5 (5.7–7.3) 145/148 4.6 (3.1–6.0) 62/72
Patients withMGMT promoter methylation
Palliative care 1.7 (0.5–3.0) 17/18 – 4/4 2.3 (2.0–2.7) 7/7 – 6/7
RT alone 5.4 (2.9–7.9) 28/30 5.1 (3.5–6.6) 10/11 7.5 (6.6–8.4) 15/15 – 3/4
CT alone 2.9 (0.8–5.0) 8/9 – 0/0 – 0/0 2.9 (0.8–5.0) 8/9
RT plus CT 13.2 (9.8–16.6) 97/106 15.0 (12.3–17.7) 41/45 9.0 (3.7–14.3) 44/46 12.0 (8.7–15.2) 12/15
Total 7.6 (6.0–9.1) 150/163 10.2 (1.8–18.6) 55/60 7.6 (6.3–8.8) 66/68 4.1 (0.6–7.6) 29/35
Patients withoutMGMT promoter methylation
Palliative care 3.0 (0.2–5.8) 19/21 – 4/4 – 10/10 – 5/7
RT alone 6.6 (5.3–7.8) 36/36 7.3 (5.3–9.3) 11/11 6.2 (6.0–6.4) 18/18 – 7/7
CT alone – 6/6 – 1/1 – 4/4 – 1/1
RT plus CT 6.4 (5.5–7.3) 110/113 5.7 (4.5–6.9) 46/46 6.8 (6.3–7.3) 47/48 7.3 (1.7–12.9) 17/19
Total 5.8 (5.0–6.6) 171/176 6.4 (5.2–7.5) 62/62 6.1 (4.8–7.5) 79/80 4.7 (3.9–5.4) 30/34
OS
Palliative care 3.0 (1.4–4.6) 36/39 0.9 (0–4.8) 8/8 2.4 (0–4.9) 17/17 3.0 (0.6–5.5) 11/14
RT alone 9.6 (8.4–10.8) 65/69 12.4 (4.2–20.5) 22/24 8.8 (7.1–10.6) 32/33 4.7 (3.5–6.0) 11/12
CT alone 6.2 (3.4–9.0) 15/15 – 1/1 – 4/4 6.2 (2.3–10.1) 10/10
RT plus CT 17.1 (14.5–19.6) 194/222 21.0 (18.9–23.1) 81/92 15.2 (11.8–18.4) 83/94 15.7 (10.1–21.3) 30/36
Total 12.8 (11.2–14.4) 310/345 17.1 (12.6–21.5) 112/125 11.7 (10.0–13.5) 136/148 8.7 (6.3–11.2) 62/72
Patients withMGMT promoter methylation
Palliative care 2.3 (1.5–3.2) 17/18 – 4/4 – 7/7 – 6/7
RT alone 9.9 (8.5–11.3) 27/30 9.6 (6.9–12.4) 9/11 10.1 (5.9–14.2) 15/15 – 3/4
CT alone 6.2 (0.1–12.4) 9/9 – 0/0 – 0/0 6.2 (0.1–12.4) 9/9
RT plus CT 27.5 (22.4–32.6) 83/106 33.2 (17.6–48.9) 35/45 24.4 (19.2–29.6) 37/46 26.2 (17.7–34.6) 11/15
Total 21.0 (15.9–26.1) 136/163 25.2 (18.3–32.1) 48/60 17.9 (8.1–27.8) 59/68 11.6 (3.6–19.6) 29/35
Patients withoutMGMT promoter methylation
Palliative care 3.4 (1.6–5.1) 19/21 – 4/4 0.8 (0.1–1.6) 10/10 – 5/7
RT alone 8.7 (8.0–9.5) 35/36 16.9 (9.0–24.7) 11/11 7.1 (3.3–10.9) 17/18 – 7/7
CT alone – 6/6 – 1/1 – 4/4 – 1/1
RT plus CT 12.8 (11.7–13.8) 108/113 14.4 (12.3–16.5) 45/46 12.6 (11.4–13.7) 46/48 9.8 (6.4–13.3) 17/19
Total 11.0 (9.6–12.4) 168/176 13.9 (12.1–15.8) 61/62 9.7 (7.9–11.5) 77/80 7.7 (4.4–10.8) 30/34
CT, alkylating chemotherapy; RT, radiotherapy;MGMT, O6-methylguanine-DNAmethyltransferase.
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months; P = 0.001); OS after incomplete resection was not
better than after biopsy only (median: 11.7 versus 8.7
months; P = 0.1; Figure 1). PFS was not inﬂuenced by EOR
when compared with biopsy only. MGMT promoter
methylation was associated with superior PFS (median: 7.6
versus 5.8 months) and OS (median: 21.0 versus 11.0
months) (each P < 0.001; Figure 1).
The subgroup analysis of patients after RT plus CT
(N = 222) revealed similar results (Figure 2): GTR was
associated with prolonged OS (median: 21.0 months;
P = 0.034), whereas OS after incomplete resection and biopsy
was similar (median: 15.2 versus 15.7 months; P = 0.4).
Survival was best in MGMT-methylated tumors undergoing
GTR (median PFS: 15.0 months/median OS: 33.2 months).
Median PFS (OS) of biopsied methylated tumors was 12.0
(26.2) months, which compared favorably with that of
unmethylated tumors after GTR [5.7 (14.4) months; Table 2;
supplementary Figure S2, available at Annals of Oncology
online].
Cox models
One variable models are given in supplementary Table S1,
available at Annals of Oncology online. Multivariate Cox
regression analyses of both the overall population and the
subpopulation receiving RT plus CT revealed similar results:
favorable prognostic factors for OS were age ≤60 years, KPS of
≥80, GTR,MGMT promoter methylation, and RT plus CT;
incomplete resection was not better than biopsy (Table 3).
discussion
The highly invasive growth characteristics of glioblastomas
explain that curative surgical treatment cannot be achieved [1].
Nevertheless, beneﬁcial cytoreductive effects of GTR have been
reported, which is deﬁned as complete resection of the contrast-
enhancing tumor parts [6, 12, 13]. According to more recently
published prospective randomized data, GTR can be expected to
be achieved in 40% of glioblastoma patients [14]. The majority
of glioblastoma patients still undergo incomplete resection and
some of them receive biopsy only, which is due to diffuse tumor
extension, affection of functional relevant areas, patient-related
risk factors (such as increased age and co-morbidity), or any
combination of these factors [9, 15]. Surprisingly, the prognostic
impact of incomplete resection when compared with biopsy
only remains unclear. The traditional view is that GTR is better
than incomplete resection and the latter is better than biopsy [2,
16]. A few studies, however, that have addressed this issue did
not analyze EOR by early postoperative MRI, did not control
the effect ofMGMT promoter methylation and applied
treatment strategies, and/or were seriously biased due to the
inﬂuence of other prognostic factors (in favor of the resection
group) [16, 17]. The current prospective observational study,
which analyzed outcome measurements of a large and
Figure 1. (A) PFS and (B) OS by the extent of resection of the overall population. (C) PFS and (D) OS byMGMT promoter methylation status of the overall
population. IR, incomplete resection; GTR, gross total resectionMGMT, O6-methylguanine-DNA methyltransferase.
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unselected patient population collected in six academic centers
with a dedicated focus on neurooncology, goes one step beyond
these limitations: outcome measurements were adjusted for the
effects ofMGMT promoter methylation and other important
patient-, tumor-, and treatment-related factors. Patients
undergoing biopsy only were used as a reference group for the
prognostic evaluation of open tumor resection. This approach
overcomes a selection bias, which always occurs when
comparing surgery responders (GTR) with nonresponders
(incomplete resection) [18]. It was remarkable that the
pretreatment prognostic proﬁle of the biopsy and the
incomplete resection groups was not as different as usually
found [16, 17]: patients of the biopsy group were only slightly
older, did not rate worse on the KPS scale, and did not exhibit
higher frequencies of eloquent tumor locations than those
undergoing incomplete resection. Hence, patients in these two
groups were relatively well balanced. It was noteworthy,
however, that biopsied patients were less likely to receive RT or
RT plus CT in this series.
In accordance with other data, we found GTR to prolong OS
[5, 6, 12, 16]. A prognostic impact of incomplete resection,
however, could not be detected: incomplete resection did not
provide advantages with respect to OS when compared with
biopsy alone. This was demonstrated in both the full analysis
Figure 2. (A) PFS and (B) OS by the extent of resection for the RT plus CT subpopulation. (C) PFS and (D) OS byMGMT promoter methylation status for
the RT plus CT subpopulation. CT, chemotherapy; GTR, gross total resection; IR, incomplete resection; RT, radiotherapy; MGMT, O6-methylguanine-DNA
methyltransferase.
Table 3. Prognostic factors for overall survival in multivariate models
Hazard ratio 95% CI P-value
All patients (N = 345)
Age ≤60 versus >60 0.52 0.41–0.66 <0.001
KPS ≥80 versus <80 0.55 0.42–0.73 <0.001
MGMTmeth. versus unmeth. 0.44 0.35–0.57 <0.001
Extent of resection
IR versus biopsy (ref.) 0.85 0.62–1.17 0.308
GTR versus biopsy (ref.) 0.60 0.43–0.84 0.003
Treatment
RT or CT versus pall. (ref.) 0.30 0.19–0.45 <0.001
RT + CT versus Pall. (ref.) 0.18 0.12–0.27 <0.001
RT + CT subpopulation (N = 222)
Age ≤60 versus >60 0.67 0.49–0.89 0.008
KPS ≥80 versus <80 0.73 0.49–1.08 0.118
MGMTmeth. versus unmeth. 0.30 0.22–0.41 <0.001
Extent of resection
IR versus biopsy (ref.) 0.78 0.50–1.20 0.257
GTR versus biopsy (ref.) 0.57 0.37–0.89 0.014
CT, chemotherapy; GTR, gross total resection; IR, incomplete resection;
KPS, Karnofsky performance score; MGMT, O6-methylguanine-DNA
methyltransferase; meth., methylated promoter status; unmeth., unmethylated
promoter status; pall., palliative care; RT, radiotherapy.
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and the subgroup analysis set of patients treated with RT plus
CT. The latter analysis was carried out to account for the
described treatment-related imbalances in the full analysis set:
still existing but not signiﬁcant differences in OS between
biopsied and incompletely resected patients in the full analysis
set resolved nearly completely in the subgroup analysis.
Beyond RT plus CT,MGMT promoter methylation turned
out to be the most powerful factor inﬂuencing OS. The outcome
in biopsied andMGMT-methylated tumors was better than in
tumors lackingMGMT promoter methylation after GTR and
RT plus CT. The study results conﬁrmed previously reported
surprisingly long OS of biopsied glioblastoma patients after
combined treatment in case of a methylatedMGMT promoter
[9]. Apparently, tumors’ biology by far outweighs the prognostic
impact of resective surgery. The prognostic models did not
indicate interactions between the inﬂuence of EOR when
compared with biopsy andMGMT promoter methylation
status. Surgery was not more effective in unmethylated or
methylated tumors.
EOR was dichotomized in the current report: those exhibiting
any gadolinium enhanced volume on their early postoperative
MRI were classiﬁed as incomplete resection. The chosen
classiﬁcation scheme is supported by the results of the post hoc
evaluation of the prospective randomized data by Stummer
et al. [6]: no distinct survival rates were found for subgroups
undergoing different degrees of EOR; only those receiving GTR
did signiﬁcantly better. Since we considered these data as the
currently most convincing ones for the prognostic evaluation of
EOR, the current study protocol was designed accordingly.
Retrospective comparison of tumor size pre- and
postoperatively has proposed a linear increase between EOR and
survival beyond a threshold of ∼78% in one more recently
published study [19]. The authors, however, have described
overlapping subpopulations regarding EOR (>78%, >80%, >90%
etc.), and it remains, therefore, unclear to which extent the
applied top–down threshold calculation has been biased by
those undergoing complete or nearly complete resection. Our
data did not support those assumptions: for those undergoing
RT plus CT, the prognostic impact of GTR was only moderate
when compared with biopsy only. Thus, the existence of true
prognostic relevant thresholds in addition to GTR seems to be
unlikely. The provided prognostic models of this study rather
indicate nonlinear correlations between EOR and outcome.
The proponents of linear correlations between EOR and
outcome are confronted with so far unresolved methodological
problems: a proper identiﬁcation of thresholds in addition to
GTR demands nonoverlapping subgroups exhibiting distinct
degrees of EOR. Thus, large multi-institutional studies are
necessary to analyze the interesting idea of a resection threshold
for glioblastoma patients. Additionally, volumetric estimation of
postsurgical MRI scans has been shown to suffer from low
interobserver agreement [20, 21].
Apparently, two different classes of glioblastoma patients
exist: those harboring resectable tumors (which should be
resected) and those harboring unresectable ones, which do not
need partial ‘debulking’ unless decompressive surgery of
pronounced and symptomatic space occupying lesions is necessary
[22]. This conclusion is important for the patient and the treating
oncologist: surgery-related complications of potentially
superﬂuous incomplete resection might delay the initiation of
adjuvant treatment, decrease quality of life, and comprise outcome
[7, 15]. Even though in the current series, the complication rate
after open tumor resection was in the lower range of reported data
in the literature [15], it was still 10 times higher than after biopsy.
We did not ﬁnd any prognostic impact of open tumor
resection on PFS. The estimation of PFS, however, might be
biased in unfavor of the resection group, particularly in case of
GTR, as usually the appearance of any new lesion after GTR is
classiﬁed as tumor recurrence; in contrast, a 25% increase in
tumor volume is required for indication of tumor progression
after incomplete resection or biopsy [11].
In summary, we found a moderate favorable prognostic effect
of GTR in the era of RT plus CT. The efﬁcacy of GTR was not
inﬂuenced ofMGMT promoter methylation, which turned out to
be the most powerful pretreatment factor for OS and PFS. In
contrast, the prognostic value of incomplete resection when
compared with biopsy only remains questionable. The indication
of biopsy should be reconsidered for unresectable tumors, as
biopsy can be safely carried out and enabled adequate histological
diagnosis and determination of theMGMT promoter
methylation status even in patients, e.g. with eloquent tumors.
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HER2 in high-risk rectal cancer patients treated in
EXPERT-C, a randomized phase II trial of neoadjuvant
capecitabine and oxaliplatin (CAPOX) and
chemoradiotherapy (CRT) with or without cetuximab
F. Sclafani1, A. Roy1, D. Cunningham1*, A. Wotherspoon1, C. Peckitt1, D. Gonzalez de Castro1,
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Background: HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer
is unclear, as conﬂicting data on the prevalence of HER2 expression in this disease have been reported. We evaluated the
prevalence of HER2 and its impact on the outcome of high-risk rectal cancer patients treated with neoadjuvant CAPOX
and CRT±cetuximab in the EXPERT-C trial.
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